Calithera Biosciences, Inc. (CALA) Receives Consensus Recommendation of “Buy” from Brokerages
Calithera Biosciences, Inc. (NASDAQ:CALA) has been given a consensus rating of “Buy” by the eight research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $14.40.
Several equities research analysts have commented on CALA shares. BidaskClub upgraded shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Friday, July 7th. Zacks Investment Research upgraded shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research note on Tuesday, July 11th. Finally, William Blair started coverage on shares of Calithera Biosciences in a research note on Thursday, October 5th. They issued an “outperform” rating on the stock.
ILLEGAL ACTIVITY NOTICE: “Calithera Biosciences, Inc. (CALA) Receives Consensus Recommendation of “Buy” from Brokerages” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/11/calithera-biosciences-inc-cala-receives-consensus-recommendation-of-buy-from-brokerages.html.
Shares of Calithera Biosciences (NASDAQ CALA) traded up 0.85% during midday trading on Wednesday, reaching $17.80. The company’s stock had a trading volume of 465,407 shares. Calithera Biosciences has a 1-year low of $2.20 and a 1-year high of $20.05. The stock has a 50 day moving average of $16.00 and a 200-day moving average of $14.57. The company’s market capitalization is $631.47 million.
Calithera Biosciences (NASDAQ:CALA) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. The firm had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. On average, equities research analysts anticipate that Calithera Biosciences will post ($0.81) earnings per share for the current year.
In related news, VP Keith Orford sold 2,120 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $15.64, for a total transaction of $9,008,640.00. The disclosure for this sale can be found here. Company insiders own 16.30% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Cubist Systematic Strategies LLC boosted its holdings in Calithera Biosciences by 10.9% during the second quarter. Cubist Systematic Strategies LLC now owns 14,972 shares of the biotechnology company’s stock worth $222,000 after buying an additional 1,472 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Calithera Biosciences by 17.5% during the first quarter. Bank of New York Mellon Corp now owns 32,688 shares of the biotechnology company’s stock worth $377,000 after buying an additional 4,863 shares in the last quarter. Raymond James Financial Services Advisors Inc. boosted its holdings in Calithera Biosciences by 68.1% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 17,000 shares of the biotechnology company’s stock worth $252,000 after buying an additional 6,885 shares in the last quarter. Legal & General Group Plc bought a new stake in Calithera Biosciences during the second quarter worth approximately $120,000. Finally, Teachers Retirement System of The State of Kentucky boosted its holdings in Calithera Biosciences by 49.2% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 27,600 shares of the biotechnology company’s stock worth $410,000 after buying an additional 9,100 shares in the last quarter. Hedge funds and other institutional investors own 71.88% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.